若您需要咨询产品或有任何技术问题,请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。

How to Measure NK Cell Killing Activity with a Standardized Potency Assay

How to Measure NK Cell Killing Activity with a Standardized Potency Assay

Natural killer (NK) cells play a central role in innate immunity by directly recognizing and eliminating tumor cells. For immunology researchers developing NK cell-based therapies, reliable and standardized methods to measure NK cell natural cytotoxicity are essential. Standardized protocols enable meaningful comparison across experiments, NK cell preparations, and tumor models, strengthening data reliability. This flow cytometry-based protocol offers a flexible framework for assessing NK cell killing activity by incorporating multiple tumor cell lines, such as K562, A549, and SKOV-3, and supporting NK cells derived from peripheral blood, cord blood, or pluripotent stem cells.

Freshly isolated peripheral blood NK cells from healthy donors are widely used in cytotoxicity assays to establish baseline NK cell function and serve as a standardized reference source of effector cells. Resting, cytokine-activated, and expanded NK cells each serve distinct roles as reference controls in cytotoxicity assays: resting NK cells define basal cytotoxic activity, activated NK cells demonstrate the upper range of killing potential, and expanded NK cells are commonly evaluated during adoptive cell therapy development to assess product quality and performance. Beyond peripheral blood-derived NK cells, NK cells can also be differentiated from CD34+ stem and progenitor cells from cord blood or from human pluripotent stem cells (hPSCs). The assays described in this protocol have been validated using NK cells from multiple sources, as detailed in the Materials section.

Flow cytometry is a common methodology used to assess NK cell potency against various tumor targets in vitro. Accordingly, this protocol integrates complementary apoptosis readouts to capture distinct stages of NK cell-mediated killing. Annexin V identifies cell death by binding to externalized phosphatidylserine, while the tetramethylrhodamine ethyl ester (TMRE) assay detects earlier loss of mitochondrial membrane potential. TMRE provides stable signal detection and reduces false negatives in adherent tumor cell lines, as it is not hindered by EDTA-based detachment. By integrating both markers, this protocol provides a robust and adaptable framework for measuring NK cell potency across diverse target cell types.

Materials

Tumor Target Cell Lines and Recommended Culture Media
  • Tumor target cells
    • K-562 cells* (ATCC; Catalog #CCL-243)
    • A549 cells* (ATCC; Catalog #CRM-CCL-185)
    • SKOV-3 cells* (ATCC; Catalog #HTB-77)
  • Fetal bovine serum (FBS) (HyClone™ Cytiva: Catalog #SH30066.03)
  • Iscove’s Modified Dulbecco’s Medium (IMDM) for K562 (Catalog #36150)
  • RPMI 1640 medium for A549 (Catalog #36750)
  • McCoy’s 5A medium for SKOV-3 (Catalog #36350)
  • Corning T-75 flasks (e.g. Catalog #200-0500)
  • D-PBS (without Ca++ and Mg++) (Catalog #37350)
  • Trypsin-EDTA (0.25%) solution (Catalog #07901)
  • CryoStor® CS10 (Catalog #100-1061)
  • 50 mL (30 x 115 mm) conical tube (e.g. Catalog #38010)

*To validate the NK cell potency assays, the following tumor cell lines were utilized: K-562 (ATCC® CCL-243™), A549 (ATCC® CCL-185™), and SKOV-3 (ATCC® HTB-77™). These cell lines were used as target populations to demonstrate the efficacy of the NK cell potency protocols and do not constitute a component of the commercial product. Users are responsible for obtaining the necessary licenses and/or agreements for the use of these cell lines within their own facilities.

NK Cell Preparation Materials
  • NK cells
    • Isolated from blood following an enrichment strategy, i.e. EasySep™ Human NK Cell Isolation Kit (Catalog #17955)** and primed overnight with activating cytokines, i.e IL-15 (Catalog #78218) at a concentration of 5 ng/mL
    • Isolated from blood and cultured and expanded during several days (10 - 15 days) using ImmunoCult™ NK Cell Expansion Kit (Catalog #100-0711)
    • Differentiated from cord blood-derived CD34+ cells (Catalog #70008) using StemSpan™ NK Cell Generation Kit (Catalog #09960)†
    • Differentiated from human pluripotent stem cells (hPSCs) using STEMdiff™ NK Cell Kit (Catalog #100-0170)†
  • Culture cell media for NK cells, i.e. ImmunoCult™ NK Cell Base Medium (Catalog #100-0712)‡ if working with peripheral blood NK cells or StemSpan™ SFEM II (Catalog #09655) if working with cord blood-derived NK cells or hPSC-derived NK cells
  • Hemocytometer (Catalog #100-1181)
  • Trypan Blue (Catalog #07050)
  • Human Recombinant IL-15 (rhIL-15), ACF (Catalog #78218)

**Based on the NK cell frequency found in peripheral blood (5 - 20%) and the EasySep™ Human NK Cell Isolation Kit recovery rate (75 - 90%), one can expect to obtain 3.75 x 106 - 1.8 x107 total NK cells from 1 x 108 peripheral blood mononuclear cells (PBMCs). Depending on the tumor cells used, number of replicates, number of plates, and effector to target ratios, the required amount of NK cells can vary significantly. It is recommended to calculate NK cell numbers needed and process the appropriate volume of PBMCs.
†NK cells from both StemSpan™ and STEMdiff™ kits were harvested at Day 21 - 23 instead of at Day 28 as suggested in the kit protocols. Our data indicated that there was no difference in cytotoxicity against the tumor target cells used in this protocol when comparing Day 21 - 23 and Day 28 NK cells. We recommend customers to optimize the duration of NK cell generation based on the expression of activating receptors as well as the ligands expressed on their target cell lines of interest.
‡Also available as part of the ImmunoCult™ NK Cell Expansion Kit. Individual kit components can be purchased by choosing the desired format from the dropdown menu on the linked product page.

Flow Cytometry-Based Potency Assay Materials

‡Also available as part of the ImmunoCult™ NK Cell Expansion Kit. Individual kit components can be purchased by choosing the desired format from the dropdown menu on the linked product page.

Protocol

Part 1: Preparation of Target Cells

Select the tumor target cell line most relevant to your study. The following procedures outline culture and preparation conditions for three commonly used models, K562 (Chronic Myelogenous Leukemia or CML-derived cell line), A549 (lung adenocarcinoma-derived cell line), and SKOV-3 (ovarian adenocarcinoma-derived cell line), representing both suspension and adherent tumor cell types.

1.1 Maintenance of Tumor Target Cells

K562
Culture medium: 10% fetal bovine serum (FBS) in Iscove’s Modified Dulbecco’s Medium (IMDM)
Subculturing procedure: Set cultures at a density of 1 - 2 x 105 cells/mL. Use 10 - 15 mL of medium in a Corning T-75 cm2 flask. Medium should be renewed every 2 - 3 days.

A549
Culture medium: 10% FBS albumin in RPMI 1640 medium
Subculturing procedure: Set cultures at a density of 1 - 2 x 105 cells/mL. Do not exceed 5 x 105 cells/mL. Use 10 - 15 mL of medium in a Corning T-75 cm2 flask. Medium should be renewed every 1 - 2 days.

  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with D-PBS to remove all traces of serum that contains trypsin inhibitors.
  3. Add 5 mL of Trypsin-EDTA solution to the flask and incubate for 8 - 10 minutes at 37°C until the cell layer is dispersed.
    Note: To avoid clumping, do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach.
  4. Add 10 mL of growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new T-75 cm2 flask.
  6. Incubate cultures at 37°C.

SKOV-3
Culture medium: 10% FBS albumin in McCoy’s 5A medium
Subculturing procedure: Set cultures at a density of 1 - 2 x 105 cells/mL. Use 10 - 15 mL of medium in a Corning T-75 cm2 flask. Medium should be renewed every 2 - 3 days.

  1. Remove and discard culture medium. Briefly rinse the cell layer with D-PBS to remove all traces of serum that contains trypsin inhibitors.
  2. Add 5 mL of Trypsin-EDTA solution to the flask and incubate for 8 - 10 minutes at 37°C until the cell layer is dispersed.
    Note: To avoid clumping, do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach.
  3. Add 10 mL of growth medium and aspirate cells by gently pipetting.
  4. Add appropriate aliquots of the cell suspension to new T-75 cm2 flasks.
  5. Incubate cultures at 37°C.

1.2 Harvesting, Labeling, and Seeding Tumor Target Cells (One Day Before Potency Assay)

  1. Harvest tumor target cells from the T-75 cm2 flask when confluency is around 80 - 90%.
    1. Cells in suspension (e.g. K-562): Harvest 10 - 15 mL of cells in suspension and transfer to a new 50 mL conical tube. Top up to 45 mL with recommended medium.
    2. Adherent cell lines (e.g. A549, SKOV-3): Aspirate and discard 10 - 15 mL of medium overlaying the cells. Wash twice with D-PBS and discard. Add 5 mL of pre-warmed Trypsin-EDTA (0.25%) solution on top of the cells and incubate for 8 - 10 minutes at 37°C until the cell layer is dispersed. Add 10 mL of recommended medium (containing 10% FBS) to neutralize trypsin after detaching the cells from the culture flask. Transfer the cells now in suspension to a new 50 mL conical tube. Top up to 45 mL with recommended medium.
  2. Centrifuge the target cells at 300 x g for 10 minutes. Decant the supernatant.
  3. Resuspend the cells in 30 - 45 mL D-PBS. Centrifuge the target cells at 300 x g for 10 minutes. Decant the supernatant.
  4. Resuspend the cell pellet in 1 - 2 mL of D-PBS. The cell concentration should be within the range of 1 x 106 - 5 x 106 cells/mL.
  5. Count the cells using trypan blue and a hemocytometer.
  6. Take an aliquot of 1 x 105 cells and dilute them in 1 mL of the recommended medium for the indicated cell line. These unlabeled cells will be used for single stain compensation controls.
  7. Prepare a solution of CellTrace™ Violet fluorescent dye at a final concentration of 5 μM using pre-warmed D-PBS.
  8. Take the amount of cells needed for labelling (at least double the amount).
  9. Centrifuge the target cells at 300 x g for 10 minutes. Decant the supernatant.
  10. esuspend the cells in the CellTrace™ Violet fluorescent dye solution at 1 x 10⁶ cells/mL and incubate for 20 minutes at 37°C (protected from light to avoid fading).
  11. Add 2-fold volume of chilled quenching solution consisting of D-PBS or basal medium with 10% FBS (v/v) and incubate the cells for 5 minutes, protected from light.
  12. Top up the 50 mL tube with the recommended medium for the cell line and centrifuge at 300 x g for 10 minutes.
  13. Decant the supernatant and resuspend the cell pellet in 1 - 2 mL of recommended medium for the cell line.
  14. Perform a cell count and dilute cells to 1 x 105 cells/mL with the recommended culture medium for each cell line.
  15. Dispense 100 μL of the cell suspension in duplicate or triplicate into the 96-well tissue culture plate to act as test samples or controls (see Table 1).
    Note: Cells in suspension (e.g. K-562) are seeded in a 96-well round-bottom microplate and adherent cells (e.g. A549 and SKOV-2) in a 96-well flat-bottom microplate.
  16. Incubate at 37°C until the following day.

Table 1. Suggested Plating Layout for Fluorescent Labeling of Tumor Target Cells Prior to the Potency Assay

1 2 3 4 5 6 7 8 9
A Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
B Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
C Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
Labeled Targets
(test sample)
D Labeled Targets
(spontaneous death)
Labeled Targets
(spontaneous death)
Labeled Targets
(spontaneous death)
E Unlabeled Targets
(unstained control)
Unlabeled Targets
(TMRE single control)
Unlabeled Targets
(Annexin V APC single control)
Unlabeled Targets
(DRAQ7™ single control)
Labeled Targets
(CellTrace™ Violet single control)
Labeled Targets
(FMO TMRE control)
Labeled Targets
(FMO Annexin V APC control)
Labeled Targets
(FMO DRAQ7™ control)
Labeled Targets
(FMO CellTrace™ Violet control)

An example layout for plating tumor target cells, both fluorescently labeled and unlabeled, in a 96-well tissue culture plate. This plate layout accommodates test samples, which include triplicates of three NK cell populations—peripheral blood NK cells, cord blood-derived NK cells, and hPSC-derived NK cells—at three effector/target (E/T) ratios (see Table 2 for details on NK cell types and ratios).
Unlabeled tumor cells should be added to the wells labeled as unstained control, TMRE single control, Annexin V APC single control, DRAQ7™ single control, and FMO CellTrace™ Violet control for compensation setup. CellTrace™ Violet-labeled tumor cells should be added to all remaining wells to act as test samples, spontaneous death controls, and additional compensation controls. In the schematic, red wells indicate test samples, blue wells indicate spontaneous target cell death controls, and green wells indicate other control conditions.
The plate layout may be adjusted based on assay requirements, including the number of test samples, E/T ratios, and replicates. We recommend using a separate plate for each tumor cell line when assessing multiple targets, particularly when combining suspension (e.g. K-562) and adherent (e.g. A549 or SKOV-3) tumor cell lines.

Part 2: Preparation of NK Cells

  1. Harvest the NK cell population of interest (peripheral blood NK cells, cytokine-primed or expanded, and/or NK cells generated from cord blood or hPSC-derived CD34+ cells) and transfer them to a 14 mL polystyrene conical tube. Centrifuge at 300 x g for 10 minutes.
  2. Decant the supernatant and resuspend the cells in fresh ImmunoCult™ NK Cell Base Medium or StemSpan SFEM II.
  3. Count cells using trypan blue and a hemocytometer. Calculate the absolute viable NK cell numbers by multiplying the total viable cell count obtained with the hemocytometer by the frequency of CD56+ cells in your cell suspension, determined by flow cytometry.
    Note: Guidance for hemocytometer-based cell counting is provided in this protocol. The frequency of C
Copyright © 2026 by STEMCELL Technologies. All rights reserved.

在线联系